Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Valneva falls as UK contract axe falls
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
Cancer continues to dominate deal making
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
